Efficacy of topical calcineurin inhibitors in vitiligo

International Journal of Dermatology

Volumn 52, Issue 4, 2013, Pages 491-496

  Wong, Russell ^a   Lin, Andrew N ^b  

^a Faculty of Medicine and Dentistry   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CLOBETASOL; CLOBETASOL PROPIONATE; MOMETASONE FUROATE; PIMECROLIMUS; PLACEBO; TACROLIMUS;

ARTICLE; DRUG EFFICACY; EXCIMER LASER; FACE INJURY; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DEFECT; SKIN PIGMENTATION; TREATMENT DURATION; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; DERMATOLOGIC AGENTS; HUMANS; OINTMENTS; SKIN CREAM; TACROLIMUS; VITILIGO;

EID: 84875061492     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05697.x     Document Type: Article

References (50)

1. Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin 2010; 28: 535-545.
2. Kawalek A, Spencer J, Phelps R. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-135.
3. Nordal EJ, Guleng GE, Ronnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol 2011; 25: 1440-1443.
4. Mehrabi D, Pandya A. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-929.
5. Lepe V, Moncada B, Castanedo-Cazares J, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585.
6. Lubaki LJ, Ghanem G, Vereecken P, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res 2010; 302: 131-137.
7. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-1069.
8. Nistico S, Chiricozzi A, Saraceno R, et al. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Photomed Laser Surg 2012; 30: 26-30.
9. Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol 2012; 78: 68-73.
10. Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol 2009; 23: 951-953.
11. Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study Photodermatol Photoimmunol Photomed 2010; 26: 230-234.
12. Fai D, Cassano N, Vena G. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 2007; 21: 916-920.
13. Hartmann A, Brocker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Derm Venereol 2008; 88: 474-479.
14. Xu AE, Zhang DM, Wei XD, et al. Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol 2009; 48: 86-90.
15. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-791.
16. Lo YH, Cheng GS, Huang CC, et al. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol 2010; 37: 125-129.
17. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-162.
18. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004; 29: 589-592.
19. Udompataikul M, Boonsupthip P, Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol 2011; 38: 536-540.
20. Sehgal VN. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo. J Eur Acad Dermatol Venereol 2009; 23: 1218-1219.
21. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 760-766.
22. Choi CW, Chang SE, Bak H, et al. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol 2008; 35: 503-507.
23. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-574.
24. Dipankar D, Amrinder JK. Tacrolimus-induced hyperpigmentation in a patch of vitiligo. SKINmed 2008; 7: 93-94.
25. Ahn BK, Kim BD, Lee SJ, Lee SH. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol 2005; 52: 532-533.
26. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-303.
27. Prats Caelles I, Herranz Pinto P, de Ayala Casado EL, de Lucas Laguna R. Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. Pediatr Dermatol 2005; 22: 86-87.
28. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19: 35-36.
29. Hartmann A, Brocker EB, Hamm H. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion. J Dtsch Dermatol Ges 2008; 6: 383-385.
30. Silverberg JI, Silverberg NB. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J Drugs Dermatol 2011; 10: 507-510.
31. Ostovari N, Passeron T, Lacour J, Ortonne J. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252-253.
32. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942-946.
33. Eryilmaz A, Seçkin D, Baba M. Pimecrolimus: a new choice in the treatment of vitiligo? J Eur Acad Dermatol Venereol 2009; 23: 1347-1348.
34. Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009; 20: 14-18.
35. Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol 2009; 26: 354-356.
36. Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol 2009; 26: 286-291.
37. Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007; 17: 55-61.
38. Sendur N, Karaman G, Saniç N, Savk E. Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 2006; 17: 338-342.
39. Seirafi H, Farnaghi F, Firooz A, et al. Pimecrolimus cream in repigmentation of vitiligo. Dermatology 2007; 214: 253-259.
40. Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat 2010; 21: 133-139.
41. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
42. Mayoral FA, Vega JM, Stavisky H, et al. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Drugs Dermatol 2007; 6: 517-521.
43. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-323.
44. Bilac DB, Ermertcan AT, Sahin MT, Ozturkcan S. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream. J Eur Acad Dermatol Venereol 2009; 23: 72-73.
45. Souza Leite RM, Craveiro Leite AA. Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol 2007; 46: 986-989.
46. Stinco G, Piccirillo F, Forcione M, et al. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol 2009; 19: 588-593.
47. Lubaki LJ, Ghanem G, Vereecken P, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus of pimecrolimus. Arch Dermatol Res 2010; 302: 131-137.
48. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65: 473-491.
49. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol 2011; 65: 493-514.
50. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663-671.